MabThera for leukemia OKed in Scotland
The Scottish Medicines Consortium, which provides guidance for treatments under the National Health Service for that country, has announced a positive recommendation for the use of Swiss drug major Roche's MabThera (rituximab) in combination with fludarabine and cyclophosphamide (FC) chemotherapy for previously-untreated patients with the UK's most common form of leukemia, chronic lymphocytic leukemia.
When added to FC chemotherapy, rituximab more than doubles the number of CLL patients achieving complete remission and halts the progression of the disease for almost a year longer than chemotherapy alone. As many as 1,850 patients in Scotland are living with CLL.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze